Erythrocyte-bound apolipoprotein B in diabetes mellitus

Completed

• Conditions: artherosclerosis; 10003216; Diabetes; 10018424

• Registration Number: NL-OMON43369
• Lead Sponsor: Sint Franciscus Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-10-05
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 133

Inclusion Criteria

Group with patients with T1DM or T2DM
- Age of 18 years of older
- Diabetes mellitus type 1 or type 2
Group with controles without T1DM or T2DM
- Age of 18 years of older

Exclusion Criteria

Group with patients with T1DM or T2DM
- Use of anti-inflammatory medication
Group with controles without T1DM or T2DM
- Diabetes mellitus type 1 or 2
- Use of anti-inflammatory medication
- Chronic inflammatory disease (e.g. rheumatoid artheritis, inflammatory bowel disease, systemic lupus erythematosus)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoint of this study will be the value of erythrocyte-bound<br /><br>apolipoprotein B in patients with diabetes mellitus type 1 or 2. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints will be the relation of erythrocyte-bound apolipoprotein B<br /><br>levels in patients with diabetes mellitus type 1 or 2 in association to<br /><br>clinical or subclinical atherosclerosis. Furthermore we will compare the level<br /><br>of and erythrocyte-bound apolipoprotein B in patients with diabetes mellitus<br /><br>against these levels in controls without diabetes mellitus. Finally, we want to<br /><br>study the levels of factors associated with complement activation in relation<br /><br>to ery- apo B values including DNA polymorphism.</p><br>